Karyopharm Therapeutics Inc. (KPTI)

NASDAQ: KPTI · IEX Real-Time Price · USD
2.26
+0.06 (2.73%)
At close: Jun 2, 2023, 4:00 PM
2.27
+0.01 (0.44%)
After-hours: Jun 2, 2023, 7:30 PM EDT
2.73%
Market Cap 257.66M
Revenue (ttm) 148.10M
Net Income (ttm) -158.02M
Shares Out 114.01M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,207,783
Open 2.22
Previous Close 2.20
Day's Range 2.15 - 2.30
52-Week Range 2.15 - 6.84
Beta 0.06
Analysts Buy
Price Target 8.25 (+265.04%)
Earnings Date May 4, 2023

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2013
Employees 385
Stock Exchange NASDAQ
Ticker Symbol KPTI
Full Company Profile

Financial Performance

In 2022, KPTI's revenue was $157.07 million, a decrease of -25.14% compared to the previous year's $209.82 million. Losses were -$165.29 million, 33.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $8.25, which is an increase of 265.04% from the latest price.

Price Target
$8.25
(265.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...

1 day ago - PRNewsWire

Karyopharm to Participate at the Jefferies Healthcare Conference

NEWTON, Mass. , June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

2 days ago - PRNewsWire

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

-  XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/o...

2 days ago - PRNewsWire
}

Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings

NEWTON, Mass. , May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abst...

1 week ago - PRNewsWire

Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

– Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of  Patient Assistant Pro...

1 month ago - PRNewsWire

Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS

– Relapsed/Refractory MDS Patients Achieved Median Overall Survival of 8.7 months – –  Historically, Median Overall Survival in this Hard to Treat Patient Population is Only 4-6 Months 1,2 – – Results...

1 month ago - PRNewsWire

Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023

-- Conference Call Scheduled for Thursday, May 4, 2023, at 8:00 a.m. ET -- NEWTON, Mass.

1 month ago - PRNewsWire

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023

–  At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in Intent to Treat Population – – Rapid, De...

1 month ago - PRNewsWire
}

Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th

Updated Safety and Efficacy Data Will be Presented in a Poster Session at AACR 2023 from All Patients Enrolled in the Phase 1 Study.

1 month ago - PRNewsWire

Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023

NEWTON, Mass. , March 14, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results fr...

2 months ago - PRNewsWire

Karyopharm to Participate at Barclays Global Healthcare Conference

NEWTON, Mass. , March 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

3 months ago - PRNewsWire

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – NEWTON, Mass. and FLORENCE, Italy , Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics In...

3 months ago - PRNewsWire

Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

-- Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company's Guidance -- -- Updated Results from the Phase 1 Study of Sel...

3 months ago - PRNewsWire
}

Karyopharm to Present at SVB Securities Global Biopharma Conference

NEWTON, Mass. , Feb. 9, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

4 months ago - PRNewsWire

Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

-- Conference Call Scheduled for Wednesday, February 15, 2023, at 8:00 a.m. ET -- NEWTON, Mass.

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

New York, New York--(Newsfile Corp. - January 18, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). S...

4 months ago - Newsfile Corp

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives

– Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO ®  (selinexor) Net Product Revenue Expected to be Approximately $157.7 Million and $120.4 Million, Respectively, Meeting Company's ...

5 months ago - PRNewsWire

Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference

NEWTON, Mass. , Jan. 4, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

5 months ago - PRNewsWire

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

– A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 – – 57% of Transfusion Independent Patients Achieved Hemoglobin Stabilization – – Company to Host Investor and...

6 months ago - PRNewsWire

Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis

– Key Opinion Leaders to Review Highlights from Updated Phase 1 Data to be Presented at ASH 2022 at Company Sponsored Event on Monday, December 12 at 8:30 AM ET – NEWTON, Mass. , Dec. 5, 2022 /PRNewsw...

6 months ago - PRNewsWire

Karyopharm Announces $165 Million Private Placement

NEWTON, Mass. , Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has enter...

6 months ago - PRNewsWire

Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass. , Nov. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

7 months ago - PRNewsWire

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

– Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third Quarter 2021– – Initiated Phase 3 Study Eva...

7 months ago - PRNewsWire

Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022

–  Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key Efficacy Endpoints of Spleen Volume Red...

7 months ago - PRNewsWire

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy , Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menar...

7 months ago - PRNewsWire